Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αklotho)

Emily G. Farrow, Erik Imel, Kenneth White

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Familial tumoral calcinosis (TC) is a rare disorder distinguished by the development of ectopic and vascular calcified masses that occur in settings of hyperphosphatemia (hFTC) and normophosphatemia (nFTC). Serum phosphorus concentrations are relatively tightly controlled by interconnected endocrine activity at the level of the intestine, kidney, and skeleton. Discovering the molecular causes for heritable forms of hFTC has shed new light on the regulation of serum phosphate balance. This review will focus upon the genetic basis and clinical approaches for hFTC, due to genes that are related to the phosphaturic hormone fibroblast growth factor-23 (FGF23). These include FGF23 itself, an FGF23-glycosylating enzyme (GALNT3), and the FGF23 co-receptor α-Klotho (αKL). Our understanding of the molecular basis of hFTC will, in the short term, aid in understanding normal phosphate balance, and in the future, provide potential insight into the design of novel therapeutic strategies for both rare and common disorders of phosphate metabolism.

Original languageEnglish
Pages (from-to)735-747
Number of pages13
JournalBest Practice and Research: Clinical Rheumatology
Volume25
Issue number5
DOIs
StatePublished - Oct 2011

Fingerprint

Phosphates
Hyperphosphatemia
Calcinosis
Serum
Skeleton
Phosphorus
Intestines
Blood Vessels
Hormones
Kidney
Hyperphosphatemic Familial Tumoral Calcinosis
fibroblast growth factor 23
Enzymes
Genes
Therapeutics

Keywords

  • α-Klotho
  • FGF-23
  • FGF23
  • GALNT3
  • HHS
  • Hyperphosphatemia
  • Phosphate
  • Tumoral calcinosis

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αklotho). / Farrow, Emily G.; Imel, Erik; White, Kenneth.

In: Best Practice and Research: Clinical Rheumatology, Vol. 25, No. 5, 10.2011, p. 735-747.

Research output: Contribution to journalArticle

@article{2919448bbc2e449dbcc232006d7e000d,
title = "Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αklotho)",
abstract = "Familial tumoral calcinosis (TC) is a rare disorder distinguished by the development of ectopic and vascular calcified masses that occur in settings of hyperphosphatemia (hFTC) and normophosphatemia (nFTC). Serum phosphorus concentrations are relatively tightly controlled by interconnected endocrine activity at the level of the intestine, kidney, and skeleton. Discovering the molecular causes for heritable forms of hFTC has shed new light on the regulation of serum phosphate balance. This review will focus upon the genetic basis and clinical approaches for hFTC, due to genes that are related to the phosphaturic hormone fibroblast growth factor-23 (FGF23). These include FGF23 itself, an FGF23-glycosylating enzyme (GALNT3), and the FGF23 co-receptor α-Klotho (αKL). Our understanding of the molecular basis of hFTC will, in the short term, aid in understanding normal phosphate balance, and in the future, provide potential insight into the design of novel therapeutic strategies for both rare and common disorders of phosphate metabolism.",
keywords = "α-Klotho, FGF-23, FGF23, GALNT3, HHS, Hyperphosphatemia, Phosphate, Tumoral calcinosis",
author = "Farrow, {Emily G.} and Erik Imel and Kenneth White",
year = "2011",
month = "10",
doi = "10.1016/j.berh.2011.10.020",
language = "English",
volume = "25",
pages = "735--747",
journal = "Best Practice and Research in Clinical Rheumatology",
issn = "1521-6942",
publisher = "Bailliere Tindall Ltd",
number = "5",

}

TY - JOUR

T1 - Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αklotho)

AU - Farrow, Emily G.

AU - Imel, Erik

AU - White, Kenneth

PY - 2011/10

Y1 - 2011/10

N2 - Familial tumoral calcinosis (TC) is a rare disorder distinguished by the development of ectopic and vascular calcified masses that occur in settings of hyperphosphatemia (hFTC) and normophosphatemia (nFTC). Serum phosphorus concentrations are relatively tightly controlled by interconnected endocrine activity at the level of the intestine, kidney, and skeleton. Discovering the molecular causes for heritable forms of hFTC has shed new light on the regulation of serum phosphate balance. This review will focus upon the genetic basis and clinical approaches for hFTC, due to genes that are related to the phosphaturic hormone fibroblast growth factor-23 (FGF23). These include FGF23 itself, an FGF23-glycosylating enzyme (GALNT3), and the FGF23 co-receptor α-Klotho (αKL). Our understanding of the molecular basis of hFTC will, in the short term, aid in understanding normal phosphate balance, and in the future, provide potential insight into the design of novel therapeutic strategies for both rare and common disorders of phosphate metabolism.

AB - Familial tumoral calcinosis (TC) is a rare disorder distinguished by the development of ectopic and vascular calcified masses that occur in settings of hyperphosphatemia (hFTC) and normophosphatemia (nFTC). Serum phosphorus concentrations are relatively tightly controlled by interconnected endocrine activity at the level of the intestine, kidney, and skeleton. Discovering the molecular causes for heritable forms of hFTC has shed new light on the regulation of serum phosphate balance. This review will focus upon the genetic basis and clinical approaches for hFTC, due to genes that are related to the phosphaturic hormone fibroblast growth factor-23 (FGF23). These include FGF23 itself, an FGF23-glycosylating enzyme (GALNT3), and the FGF23 co-receptor α-Klotho (αKL). Our understanding of the molecular basis of hFTC will, in the short term, aid in understanding normal phosphate balance, and in the future, provide potential insight into the design of novel therapeutic strategies for both rare and common disorders of phosphate metabolism.

KW - α-Klotho

KW - FGF-23

KW - FGF23

KW - GALNT3

KW - HHS

KW - Hyperphosphatemia

KW - Phosphate

KW - Tumoral calcinosis

UR - http://www.scopus.com/inward/record.url?scp=82955178697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955178697&partnerID=8YFLogxK

U2 - 10.1016/j.berh.2011.10.020

DO - 10.1016/j.berh.2011.10.020

M3 - Article

VL - 25

SP - 735

EP - 747

JO - Best Practice and Research in Clinical Rheumatology

JF - Best Practice and Research in Clinical Rheumatology

SN - 1521-6942

IS - 5

ER -